酒精性肝硬化患者酒精使用治疗的成本效益分析
本研究模拟代偿期酒精性肝硬化(AC)患者终身队列,从医疗与社会视角评估药物辅助治疗(MATs)和咨询的成本效益。结果显示,与不干预相比,MATs和咨询从医疗视角具有成本节约性,阿坎酸和纳曲酮成本最低且QALYs最高,在常用阈值下仍具成本效益。
要点
- MATs和咨询在代偿期AC患者中极具成本效益,部分情况可节约成本。
- 阿坎酸和纳曲酮成本最低且提供最多QALYs。
- 即使效果下降,干预仍低于10万美元/QALY阈值。
核心结论
- 在代偿期AC患者中,MATs和咨询是极具成本效益的干预措施,部分情况下可节约成本。
- 卫生政策应强调并适当补偿这些干预措施。
研究设计与样本
- 模拟代偿期AC患者终身队列,接受肝病门诊照护。
- 从医疗和社会视角估算成本(2017年美元)和QALYs。
- 转移概率、成本和健康效用权重取自文献。
- 治疗效应基于雇主保险AC患者的研究。
主要发现
- 与不干预相比,MATs和咨询从医疗视角具有成本节约性。
- 阿坎酸和纳曲酮成本最低且提供最多QALYs。
- 若MATs和咨询效果下降,仍低于10万美元/QALY阈值。
- 敏感性分析显示主要发现稳健。
关键数值与推荐
- 成本以2017年美元计。
- 效益以QALYs衡量。
- 常用成本效益阈值为10万美元/QALY。
临床怎么用
- 应鼓励更广泛使用咨询和MATs帮助AC患者戒酒。
- 支付方应考虑报销并适当补偿这些干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alcohol use treatment such as medication-assisted therapies (MATs) and counseling are available and effective in promoting alcohol abstinence. We sought to explore the cost-effectiveness of different alcohol use treatments among patients with compensated alcohol-related cirrhosis (AC). METHODS: We simulated a cohort of patients with compensated AC receiving care from a hepatology clinic over their lifetimes. We estimated costs (in 2017 US$) and benefits in terms of quality-adjusted life years (QALYs) gained from healthcare and societal perspectives. Transition probabilities, costs, and health utility weights were taken from the literature. Treatment effects of FDA-approved MATs (acamprosate and naltrexone) and non-FDA approved MATs (baclofen, gabapentin, and topiramate) and counseling were based on a study of employer-insured patients with AC. We calculated incremental cost-effectiveness ratios (ICERs) and performed one-way and probabilistic sensitivity analyses to understand the impact of parameter uncertainty. RESULTS: Compared to a do-nothing scenario, MATs and counseling were found to be cost-saving from a healthcare perspective, which means that they provide more benefits with less costs than no intervention. Compared to other interventions, acamprosate and naltrexone cost the least and provide the most QALYs. If the effectiveness of MATs and counseling decreased, these interventions would still be cost-effective based on the commonly used $100,000 per QALY gained threshold. Several sensitivity and scenario analyses showed that our main findings are robust. CONCLUSIONS: Among patients with compensated AC, MATs and counseling are extremely cost-effective, and in some cases cost-saving, interventions to prevent decompensation and improve health. Health policies (e.g. payer reimbursement) should emphasize and appropriately compensate for these interventions. LAY SUMMARY: Alcohol use treatments, including physician counseling and medication-assisted therapies (MATs), improve the outcomes of patients with compensated alcohol-related cirrhosis, though use and access have remained suboptimal. In this study, we found that counseling and MATs are extremely cost-effective, and in some cases cost-saving, interventions to help patients with alcohol-related cirrhosis abstain from alcohol and improve their health. Wider use of these interventions should be encouraged.
引用
- Avanceña ALV, Miller N, Uttal SE, et al. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. J Hepatol. 2020. PMID: 33326815. doi:10.1016/j.jhep.2020.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。